Targeting IAP proteins for therapeutic intervention in cancer

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Nature reviews. Drug discovery

• Publication date

  2012-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nrd3627PMID 22293567
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact on Prognosis

  2014cited by this paper
• Prognostic value of Smac expression in rectal cancer patients treated with neoadjuvant therapy

  2012cited by this paper
• RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis

  2012cited by this paper
• Cellular Inhibitors of Apoptosis Are Global Regulators of NF-κB and MAPK Activation by Members of the TNF Family of Receptors

  2012cited by this paper
• Nuclear cIAP1 overexpression is a tumor stage- and grade-independent predictor of poor prognosis in human bladder cancer patients.

  2012cited by this paper
• Prognostic significance of smac/DIABLO in endometrioid endometrial cancer.

  2011cited by this paper
• Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study.

  2011cited by this paper
• SHARPIN is a component of the NF-κB-activating linear ubiquitin chain assembly complex

  2011cited by this paper
• Smac Mimetics Activate the E3 Ligase Activity of cIAP1 Protein by Promoting RING Domain Dimerization*

  2011cited by this paper
• Linear ubiquitination prevents inflammation and regulates immune signalling

  2011cited by this paper
• Smac mimetic bypasses apoptosis resistance in FADD- or caspase-8-deficient cells by priming for tumor necrosis factor α-induced necroptosis.

  2011cited by this paper
• Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

  2011cited by this paper
• Down-regulation of XIAP by AEG35156 in paediatric tumour cells induces apoptosis and sensitises cells to cytotoxic agents.

  2011cited by this paper
• A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment.

  2011cited by this paper
• A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo.

  2011cited by this paper
• Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study.

  2011cited by this paper
• Novel X‐linked inhibitor of apoptosis inhibiting compound as sensitizer for TRAIL‐mediated apoptosis in chronic lymphocytic leukaemia with poor prognosis

  2011cited by this paper
• Patent review.

  2011cited by this paper
• X-linked inhibitor of apoptosis positive nuclear labeling: a new independent prognostic biomarker of breast invasive ductal carcinoma

  2011cited by this paper
• Therapeutic Potential and Molecular Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic SM-164 in Combination with TRAIL for Cancer Treatment

  2011cited by this paper
• SHARPIN forms a linear ubiquitin ligase complex regulating NF-κB activity and apoptosis

  2011cited by this paper
• NF-κB Is Required for Smac Mimetic-Mediated Sensitization of Glioblastoma Cells for γ-Irradiation–Induced Apoptosis

  2011cited by this paper
• Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death

  2011cited by this paper
• Abstract LB-406: Phase 1 study of the Smac mimetic TL32711 in adult subjects with advanced solid tumors and lymphoma to evaluate safety, pharmacokinetics, pharmacodynamics, and antitumor activity

  2011cited by this paper
• cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production

  2011cited by this paper
• Requirement of nuclear factor κB for Smac mimetic-mediated sensitization of pancreatic carcinoma cells for gemcitabine-induced apoptosis.

  2011cited by this paper
• Expression of inhibitor of apoptosis protein (IAP) livin/BIRC7 in acute leukemia in adults: correlation with prognostic factors and outcome.

  2011cited by this paper
• Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012

  2011cited by this paper
• Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis

  2011cited by this paper
• Design, synthesis and evaluation of monovalent Smac mimetics that bind to the BIR2 domain of the anti-apoptotic protein XIAP.

  2011cited by this paper
• Antagonists Induce a Conformational Change in cIAP1 That Promotes Autoubiquitination

  2011cited by this paper
• Correlation of Smac/DIABLO protein expression with the clinico-pathological features of breast cancer patients.

  2011cited by this paper
• Natural IAP inhibitor Embelin enhances therapeutic efficacy of ionizing radiation in prostate cancer.

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Abstract 2775: A phase I study of LCL161, an oral IAP inhibitor, in patients with advanced cancer

  2010cited by this paper
• Smac mimetics: implications for enhancement of targeted therapies in leukemia

  2010cited by this paper
• IAP inhibitors enhance co-stimulation to promote tumor immunity

  2010cited by this paper
• Influence of high expression of Smac/DIABLO protein on the clinical outcome in acute myeloid leukemia patients.

  2010cited by this paper
• Targeting X-linked inhibitor of apoptosis protein to increase the efficacy of endoplasmic reticulum stress-induced apoptosis for melanoma therapy.

  2010cited by this paper
• Targeting mitochondria for cancer therapy

  2010cited by this paper
• Classical and/or alternative NF-kappaB pathway activation in multiple myeloma.

  2010cited by this paper
• Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib

  2010cited by this paper
• Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-α-dependent manner

  2010cited by this paper
• A smac mimetic reduces TNF Related Apoptosis Inducing Ligand (TRAIL)‐induced invasion and metastasis of cholangiocarcinoma cells

  2010cited by this paper
• X-Linked Inhibitor of Apoptosis Protein Inhibits Apoptosis in Inflammatory Breast Cancer Cells with Acquired Resistance to an ErbB1/2 Tyrosine Kinase Inhibitor

  2010cited by this paper
• Identification of c-FLIPL and c-FLIPS as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells

  2010cited by this paper
• Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML

  2010cited by this paper
• XIAP-mediated protection of H460 lung cancer cells against cisplatin.

  2010cited by this paper
• Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a possible induction of an anti-inflammatory cytokine response.

  2010cited by this paper
• c‐IAP1 and UbcH5 promote K11‐linked polyubiquitination of RIP1 in TNF signalling

  2010cited by this paper
• XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38− cells in a phase 1/2 study of patients with relapsed/refractory AML

  2010cited by this paper
• XIAP expression is post‐transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T‐cell ALL

  2010cited by this paper
• Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells

  2010cited by this paper
• Prognostic significance of second mitochondria-derived activator of caspase (Smac/DIABLO) expression in bladder cancer and target for therapy.

  2010cited by this paper
• TRAIL-Induced Apoptosis Is Preferentially Mediated via TRAIL Receptor 1 in Pancreatic Carcinoma Cells and Profoundly Enhanced by XIAP Inhibitors

  2010cited by this paper
• Prognostic significance of XIAP expression in DLBCL and effect of its inhibition on AKT signalling

  2010cited by this paper
• Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer.

  2010cited by this paper
• Small-molecule pan-IAP antagonists: a patent review

  2010cited by this paper
• Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia.

  2010cited by this paper
• Small-Molecule XIAP Inhibitors Enhance γ-Irradiation-Induced Apoptosis in Glioblastoma

  2009cited by this paper
• Design of Small‐Molecule Peptidic and Nonpeptidic Smac Mimetics

  2009cited by this paper
• Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer

  2009cited by this paper
• Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma.

  2009cited by this paper
• Down-regulation of c-FLIP Enhances death of cancer cells by smac mimetic compound.

  2009cited by this paper
• Orally bioavailable antagonists of inhibitor of apoptosis proteins based on an azabicyclooctane scaffold.

  2009cited by this paper
• Small molecule XIAP inhibitors sensitize childhood acute leukemia cells for CD95‐induced apoptosis

  2009cited by this paper
• Small-molecule XIAP inhibitors enhance gamma-irradiation-induced apoptosis in glioblastoma.

  2009cited by this paper
• A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB

  2009cited by this paper
• Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists.

  2009cited by this paper
• Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.

  2009cited by this paper
• Expression of livin in gastric cancer and induction of apoptosis in SGC-7901 cells by shRNA-mediated silencing of livin gene.

  2009cited by this paper
• Involvement of linear polyubiquitylation of NEMO in NF-κB activation

  2009cited by this paper
• Overexpression of X-linked Inhibitor of Apoptosis Protein (XIAP) is an Independent Unfavorable Prognostic Factor in Childhood de Novo Acute Myeloid Leukemia

  2009cited by this paper
• Ubiquitin binding modulates IAP antagonist-stimulated proteasomal degradation of c-IAP1 and c-IAP2(1).

  2009cited by this paper
• Classical and/or Alternative NFkB pathway activation in multiple myeloma

  2009cited by this paper
• MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression.

  2009cited by this paper
• Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction.

  2009cited by this paper
• Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.

  2009cited by this paper
• Experimental Therapeutics , Molecular Targets , and Chemical Biology A Novel Paradigm to Trigger Apoptosis in Chronic Lymphocytic Leukemia

  2009cited by this paper
• The XIAP inhibitor Embelin enhances TRAIL-mediated apoptosis in malignant glioma cells by down-regulation of the short isoform of FLIP.

  2009cited by this paper
• Expression of X‐linked inhibitor of apoptosis protein in human colorectal cancer and its correlation with prognosis

  2009cited by this paper
• XIAP discriminates between type I and type II FAS-induced apoptosis

  2009cited by this paper
• Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment

  2009cited by this paper
• Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma

  2009cited by this paper
• Unleashing the therapeutic potential of NOD-like receptors

  2009cited by this paper
• Tumor resistance to apoptosis

  2009cited by this paper
• A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC

  2009cited by this paper
• Targeting inhibitor of apoptosis proteins for therapeutic intervention.

  2009cited by this paper
• Clinical significance of Smac/DIABLO expression in colorectal cancer.

  2009cited by this paper
• X Chromosome-linked Inhibitor of Apoptosis Regulates Cell Death Induction by Proapoptotic Receptor Agonists

  2009cited by this paper
• High nuclear Livin expression is a favourable prognostic indicator in renal cell carcinoma

  2008cited by this paper
• (Un)expected roles of c-IAPs in apoptotic and NFκB signaling pathways

  2008cited by this paper
• Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas.

  2008cited by this paper
• Expression of X‐linked inhibitor‐of‐apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence

  2008cited by this paper
• (Un)expected roles of c-IAPs in apoptotic and NFkappaB signaling pathways.

  2008cited by this paper
• Downregulation of XIAP expression in ovarian cancer cells induces cell death in vitro and in vivo

  2008cited by this paper
• Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins.

  2008cited by this paper
• Structures of the cIAP2 RING Domain Reveal Conformational Changes Associated with Ubiquitin-conjugating Enzyme (E2) Recruitment*

  2008cited by this paper
• IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-κB as well as cell survival and oncogenesis

  2008influential reference
• Expression levels of the mitochondrial IAP antagonists Smac/DIABLO and Omi/HtrA2 in clear-cell renal cell carcinomas and their prognostic value

  2008cited by this paper

• GC-MS Metabolite Profiling and Induction of Cell Death by Sphaeranthus amaranthoides Leaf Extracts.

  2026cites this paper
• Protein Kinase B(AKT)-Mediated Lysosomal-Mitochondrial Apoptotic Pathway: Molecular Mechanisms and Implications for Post-Mortem Muscle Tenderization.

  2026cites this paper
• IAP Antagonists Selectively Eliminate Therapy-Induced Senescent Cancer Cells via TNFα-Independent Apoptosis.

  2026cites this paper
• Survivin/BIRC5-derived peptide disrupts survivin dimerization and cell division and induces multifaceted anti-cancer effects

  2026cites this paper
• Reduced expression of BIRC2 and BIRC3 associated with longer survival in pediatric high-grade gliomas

  2026cites this paper
• Discovery, preclinical safety, and efficacy characterization of SMAC mimetic S-016-1348 as a potential cancer therapeutic.

  2026cites this paper
• Pseudolaric acid B promotes lung cancer cells ferroptosis depending on JNK/ERK-mediated upregulation of survivin.

  2026cites this paper
• IAPs in cancers: molecular mechanisms, clinical prognostic value, and translational therapeutic potential

  2026cites this paper
• Research progress on resistance mechanisms to CAR-T cell therapy in diffuse large B-cell lymphoma.

  2026cites this paper
• Expanding the universe of T-PLL targets.

  2025cites this paper
• BIRC5 expression correlates with immunosuppressive phenotype and predicts inferior response to immunotherapy in lung adenocarcinoma

  2025cites this paper
• Tazarotene-Induced Gene 3 (TIG3) Induces Apoptosis in Melanoma Cells Through the Modulation of Inhibitors of Apoptosis Proteins

  2025cites this paper
• Citrate-capped AuNPs-induced redox reprogramming modulates the TP53-BAX/BCL2-CASP3 Axis, reinforcing antioxidant defense and promoting apoptotic signaling in liver Cancer.

  2025cites this paper
• The structural basis of drugs targeting protein-protein interactions uncovered with the protein-ligand interaction profiler PLIP

  2025cites this paper
• The role of apoptosis and its potential as a therapeutic target in inflammatory bowel disease associated with colorectal cancer.

  2025cites this paper
• Cathepsin B Activatable Fluorescent Probe for Antitumor Efficiency Feedback: Attempt To Detect Certain Apoptotic Cells.

  2025cites this paper
• Blocking XIAP:CASP7-p19 selectively induces apoptosis of CASP3/DR malignancies by a novel reversible small molecule

  2025cites this paper
• Synthesis of the 1,5-Diazabicyclo[6.3.0]dodecane Core Structure of Xevinapant.

  2025cites this paper
• BLID is a drug-responsive target of FOXO3a and multi-omics analysis reveals survival mechanisms and therapeutic vulnerabilities in BLID-deficient breast cancer cells

  2025cites this paper
• Combining BET inhibition with SMAC mimetics restricts tumor growth and triggers immune surveillance in preclinical cancer models

  2025cites this paper
• ANTP-SmacN7 enhances radiosensitivity in TPC-1 cells through XIAP-mediated activation of apoptotic protein

  2025cites this paper
• Transcriptional remodeling shapes therapeutic vulnerability to necroptosis in acute lymphoblastic leukemia

  2025cites this paper
• Targeting cIAP2 in a novel senolytic strategy prevents glioblastoma recurrence after radiotherapy

  2025cites this paper
• Recent progress in the treatment of locally advanced head and neck squamous cell carcinomas

  2025cites this paper
• Restoring apoptosis in breast cancer via peptide mediated disruption of survivin IAP interaction

  2025cites this paper
• Evolving Neoadjuvant, Adjuvant, and Concurrent Systemic Therapy Strategies in Head and Neck Squamous Carcinoma.

  2025cites this paper
• Enhanced glioblastoma immunotherapy via SMAC mimetic dose escalation and TGFβ blockade

  2025cites this paper
• Cancer cell death: Cell-autonomous and immunogenic dimensions.

  2025cites this paper
• The lncrnas: innovative multifunctional players of drug resistance in colorectal cancer

  2025cites this paper
• Tumor-microbe transkingdom interactions in cancers at body interfaces: mechanisms of neutrophil lifespan extension and functional reprogramming with therapeutic implications.

  2025cites this paper
• Targeting Protein-Protein Interactions in Hematologic Malignancies.

  2025cites this paper
• Caspases as master regulators of programmed cell death: apoptosis, pyroptosis and beyond

  2025cites this paper
• Prenylated Chalcones as Anticancer Agents Against Castration-Resistant Prostate Cancer

  2025cites this paper
• BIRC5 dependency defines a targetable vulnerability in TP53 mutant acute myeloid leukemia

  2025cites this paper
• Targeting anti-apoptotic mechanisms in tumour cells: Strategies for enhancing Cancer therapy.

  2025cites this paper
• Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer

  2025cites this paper
• Etoposide-loaded lipopolymer nanoparticles promote Smac minetic activity against inhibitor of apoptosis protein for glioblastoma treatment.

  2025cites this paper
• MDM1 overexpression promotes p53 expression and cell apoptosis to enhance therapeutic sensitivity to chemoradiotherapy in patients with colorectal cancer

  2025cites this paper
• Dose escalation of tolinapant (ASTX660) in combination with standard radical chemoradiotherapy in cervical cancer : a study protocol for a phase 1b TiTE-CRM clinical trial (CRAIN) in UK secondary care centres

  2024cites this paper
• USP36 inhibits apoptosis by deubiquitinating cIAP1 and survivin in colorectal cancer cells

  2024cites this paper
• Research Progress in the Use of Small Molecule Smac Mimetics in Combination Therapy of Cancer.

  2024cites this paper
• PROTAC Beyond Cancer- Exploring the New Therapeutic Potential of Proteolysis Targeting Chimeras.

  2024cites this paper
• Clinically used drug arsenic trioxide targets XIAP and overcomes apoptosis resistance in an organoid-based preclinical cancer model

  2024cites this paper
• Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies.

  2024cites this paper
• Evasion of apoptosis and treatment resistance in squamous cell carcinoma of the head and neck.

  2024cites this paper
• E-cadherin re-expression: Its potential in combating TRAIL resistance and reversing epithelial-to-mesenchymal transition.

  2024cites this paper
• SMAC Mimetics for the Treatment of Lung Carcinoma: Present Development and Future Prospects.

  2024cites this paper
• The Role of miR-29a and miR-143 on the Anti-apoptotic MCL-1/cIAP-2 Genes Expression in EGFR Mutated Non-small Cell Lung Carcinoma Patients

  2024cites this paper
• Strategies to address key challenges of metallacycle/metallacage-based supramolecular coordination complexes in biomedical applications.

  2024cites this paper
• The preclinical pharmacokinetics of Tolinapant—A dual cIAP1/XIAP antagonist with in vivo efficacy

  2024cites this paper
• cIAP2 supports the cell growth-promoting activity of FMR1 in gastric cancer via CARD-RING domains.

  2024cites this paper
• Dual roles of inflammatory programmed cell death in cancer: insights into pyroptosis and necroptosis

  2024cites this paper
• Targeting inhibitor of apoptosis proteins (IAPs) enhances susceptibility of oral squamous carcinoma cells to cisplatin.

  2024cites this paper
• Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design.

  2024cites this paper
• Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape.

  2024cites this paper
• Targeted Cancer Stem Cell Therapeutics: An Update.

  2024cites this paper
• Regulated cell death in glioma: promising targets for natural small-molecule compounds

  2024cites this paper
• Exploiting acquired vulnerability to develop novel treatments for cholangiocarcinoma

  2024cites this paper
• E3 ubiquitin ligase gene BIRC3 modulates TNF-induced cell death pathways and promotes aberrant proliferation in rheumatoid arthritis fibroblast-like synoviocytes

  2024cites this paper
• Targeting regulated cell death pathways in cancers for effective treatment: a comprehensive review

  2024cites this paper
• Inhibitor of apoptosis proteins (IAP) inhibitor APG-1387 monotherapy or in combination with programmed cell death 1 (PD-1) inhibitor toripalimab in patients with advanced solid tumors: results from two phase I trials

  2024cites this paper
• Exploring the Therapeutic Potential for Breast Cancer of Phytochemicals and Secondary Metabolites in Marjoram, Thyme, and Persimmon

  2024cites this paper
• Astrocytes and the tumor microenvironment inflammatory state dictate the killing of glioblastoma cells by Smac mimetic compounds

  2024cites this paper
• Tailoring glioblastoma treatment based on longitudinal analysis of post-surgical tumor microenvironment

  2024cites this paper
• The novel drug candidate S2/IAPinh improves survival in models of pancreatic and ovarian cancer

  2024cites this paper
• Simultaneous XIAP and cIAP1/2 inhibition by a dimeric SMAC mimetic AZD5582 induces apoptosis in multiple myeloma.

  2023cites this paper
• Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins

  2023cites this paper
• The research progress of crosstalk mechanism of autophagy and apoptosis in diabetic vascular endothelial injury.

  2023cites this paper
• Molecular basis for nuclear accumulation and targeting of the inhibitor of apoptosis BIRC2

  2023cites this paper
• Advances in the Application of Apoptotic Proteins and Alternative Splicing in Tumor Therapy: A Narrative Review

  2023cites this paper
• Higher Mixed lineage Kinase Domain-like protein (MLKL) is associated with worst overall survival in adult-type diffuse glioma patients

  2023cites this paper
• Synergistic effect of smac-mimetic and poly (I:C) on apoptosis of cholangiocarcinoma cells

  2023cites this paper
• Anticancer, anti-inflammatory, and immune modulatory activity of ferulic acid fructo-oligosaccharide conjugated microparticle

  2023cites this paper
• The Effect of Xevinapant Combined with Ionizing Radiation on HNSCC and Normal Tissue Cells and the Impact of Xevinapant on Its Targeted Proteins cIAP1 and XIAP

  2023cites this paper
• Apoptosis: a Janus bifrons in T-cell immunotherapy

  2023cites this paper
• Advances in molecular targeted therapies to increase efficacy of (chemo)radiation therapy

  2023cites this paper
• Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design.

  2023cites this paper
• Small molecules targeting protein–protein interactions for cancer therapy

  2023cites this paper
• Computational Tool to Design Small Synthetic Inhibitors Selective for XIAP-BIR3 Domain

  2023cites this paper
• Heterobifunctional Ligase Recruiters Enable pan-Degradation of Inhibitor of Apoptosis Proteins

  2023cites this paper
• Mitochondrial dysfunction and drug targets in multiple myeloma

  2023cites this paper
• MLKL and other necroptosis-related genes promote the tumor immune cell infiltration, guiding for the administration of immunotherapy in bladder urothelial carcinoma

  2023cites this paper
• Model‐Informed Selection of the Recommended Phase III Dose of the Inhibitor of Apoptosis Protein Inhibitor, Xevinapant, in Combination with Cisplatin and Concurrent Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

  2023cites this paper
• Recognition and reprogramming of E3 ubiquitin ligase surfaces by α-helical peptides

  2023cites this paper
• Birinapant selectively enhances immunotoxin‐mediated killing of cancer cells conditional on the IAP protein levels within target cells

  2023cites this paper
• TRAIL-Sensitizing Effects of Flavonoids in Cancer

  2023cites this paper
• P-TEFb promotes cell survival upon p53 activation by suppressing intrinsic apoptosis pathway

  2023cites this paper
• Self-synthesized second mitochondria-derived activator of caspase (SMAC) mimetic TP-WY-1345 enhances the radiosensitivity of NSCLC cells H1299 by targeting anti-apoptotic protein cIAP1

  2023cites this paper
• A massive machine regulates cell death

  2023cites this paper
• XIAP deletion sensitizes mice to TNF-induced and RIP1-mediated death

  2023cites this paper
• Natural Flavonoids Quercetin and Kaempferol Targeting G2/M Cell Cycle-Related Genes and Synergize with Smac Mimetic LCL-161 to Induce Necroptosis in Cholangiocarcinoma Cells

  2023cites this paper
• Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.

  2023cites this paper
• SMAC mimetics inhibit human T cell proliferation and fail to augment type 1 cytokine responses.

  2023cites this paper
• Towards a templated reaction that translates RNA in cells into a proaptotic peptide‐PNA conjugate

  2023cites this paper
• Cannabidiol regulates apoptosis and autophagy in inflammation and cancer: A review

  2023cites this paper
• The Therapeutic Potential of Pyroptosis in Melanoma

  2023cites this paper
• Involvement of Both Extrinsic and Intrinsic Apoptotic Pathways in Tridecylpyrrolidine-Diol Derivative-Induced Apoptosis In Vitro

  2023cites this paper
• The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity

  2022cites this paper
• Apoptosis, necroptosis, and pyroptosis in health and disease

  2022cites this paper
• Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs

  2022cites this paper